Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 10
2003 25
2004 30
2005 13
2006 20
2007 29
2008 31
2009 41
2010 25
2011 33
2012 23
2013 37
2014 33
2015 32
2016 33
2017 24
2018 23
2019 27
2020 76
2021 68
2022 39
2023 32
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

621 results

Results by year

Filters applied: . Clear all
Page 1
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients.
Piciocchi A, Cipriani M, Messina M, Marconi G, Arena V, Soddu S, Crea E, Feraco MV, Ferrante M, La Sala E, Fazi P, Buccisano F, Voso MT, Martinelli G, Venditti A, Vignetti M. Piciocchi A, et al. Among authors: martinelli g. EJHaem. 2024 Mar 15;5(2):353-359. doi: 10.1002/jha2.873. eCollection 2024 Apr. EJHaem. 2024. PMID: 38633115 Free PMC article.
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee D, Hamidi H, Ott MG, Hong WJ, Andreeff M. Konopleva MY, et al. Among authors: martinelli g. Clin Lymphoma Myeloma Leuk. 2024 Jan 18:S2152-2650(24)00036-3. doi: 10.1016/j.clml.2024.01.007. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38378362 Free article.
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld AW, Rousselot P, Ribera JM, Bassan R. Gökbuget N, et al. Among authors: martinelli g. Blood. 2024 Feb 2:blood.2023023568. doi: 10.1182/blood.2023023568. Online ahead of print. Blood. 2024. PMID: 38306595
Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann OG, Rijneveld AW, Rousselot P, Ribera JM, Bassan R. Gökbuget N, et al. Among authors: martinelli g. Blood. 2024 Jan 31:blood.2023020794. doi: 10.1182/blood.2023020794. Online ahead of print. Blood. 2024. PMID: 38295337
Data Science for Health Image Alignment: A User-Friendly Open-Source ImageJ/Fiji Plugin for Aligning Multimodality/Immunohistochemistry/Immunofluorescence 2D Microscopy Images.
Piccinini F, Tazzari M, Tumedei MM, Stellato M, Remondini D, Giampieri E, Martinelli G, Castellani G, Carbonaro A. Piccinini F, et al. Among authors: martinelli g. Sensors (Basel). 2024 Jan 11;24(2):451. doi: 10.3390/s24020451. Sensors (Basel). 2024. PMID: 38257548 Free PMC article.
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, Agostinelli C, Sabattini E, Orsatti A, Ferrari A, Capirossi G, Servili C, Ghelli Luserna di Rorà A, Martinelli G, Simonetti G, Rosti G. Bochicchio MT, et al. Among authors: martinelli g. Int J Mol Sci. 2023 Dec 21;25(1):118. doi: 10.3390/ijms25010118. Int J Mol Sci. 2023. PMID: 38203288 Free PMC article.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, Özcan M, Samoilova O, Tolbert JA, Trudel GC, Xiu L, Vey N, Wei AH. Pabst T, et al. Among authors: martinelli g. Lancet Haematol. 2023 Nov;10(11):e902-e912. doi: 10.1016/S2352-3026(23)00207-7. Lancet Haematol. 2023. PMID: 37914483 Clinical Trial.
621 results